Lucid Diagnostics
Lucid Diagnostics' revenue rose 8.3% to $5 million in fiscal 2025. Its operating margin was −1,054.8%, up from −1,059.6% a year earlier. Free cash flow was −$47 million. The diluted share count rose 101.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Lucid Diagnostics lost money in fiscal 2025: a net loss of $58 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 54 | 22 | 19 | 22 | 35 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −41.6x | −7,031.4x | −116.5x | −1,771.2x | −2,256.4x |
| Current ratio | 13.4x | 2.9x | 0.8x | 1.1x | 1.3x |
| Quick ratio | 13.4x | 2.9x | 0.7x | 1.1x | 1.3x |
Cash flow
Projections
Project Lucid Diagnostics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $245,000 of Lucid Diagnostics shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| May 20, 2026 | Dennis MatheisDirector | Bought | 245,000 | $1.00 | $245,000 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | −943.5% | −983.7% |
| Altman Z'' | −31.81 | −31.13 | −28.53 |
| Accruals ratio | −66.4% | −4.8% | −32.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | Pass |
| Revenue rose relative to assets | Pass | Pass | Fail |
| F-score | — | — | — |
Compare
Put Lucid Diagnostics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Lucid Diagnostics | FY25 | 8.3% | −1,054.8% | −992.0% | — | — | — | |
| Picard Medical | FY25 | 12.5% | −268.4% | — | — | — | — | Compare |
| Intelligent Bio Solutions | FY26 | 38.1% | −299.1% | −285.9% | — | — | — | Compare |
| Neuraxis | FY25 | 32.9% | −219.4% | −181.1% | — | — | — | Compare |
| Beyond Air | FY26 | 107.3% | −378.2% | −249.6% | — | — | — | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | 0 | 0 | 2 | 4 | 5 |
| Revenue growth | — | — | −24.6% | 544.0% | 79.0% | 8.3% |
| Gross profit | — | 0 | 0 | — | −3 | −2 |
| Research and development | 5 | 9 | 11 | 7 | 6 | 6 |
| Operating income | −8 | −27 | −56 | −48 | −46 | −50 |
| Net income | −8 | −28 | −56 | −53 | −46 | −58 |
| Diluted EPS (US$) | −0.59 | −1.51 | −1.55 | −1.26 | −1.05 | — |
| Diluted shares (millions) | 14 | 19 | 36 | 42 | 50 | 102 |
| Cash flow | ||||||
| Cash from operations | −6 | −18 | −30 | −33 | −44 | −46 |
| Capital expenditure | — | 1 | 3 | — | 0 | 0 |
| Free cash flow | — | −19 | −33 | — | −44 | −47 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 9 | 14 | 6 | 4 | 4 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 0 | 54 | 22 | 19 | 22 | 35 |
| Debt incl. finance leases | — | — | — | — | — | — |
| Total assets | 2 | 59 | 32 | 27 | 31 | 40 |
| Total liabilities | 16 | 4 | 10 | 30 | 25 | 30 |
| Shareholders' equity | −14 | 55 | 23 | −2 | 5 | 11 |
| Margins and ratios | ||||||
| Gross margin | — | 100.0% | 100.0% | — | −63.4% | −41.7% |
| Operating margin | — | −5,483.8% | −14,920.7% | −1,996.8% | −1,059.6% | −1,054.8% |
| Net margin | — | −5,615.6% | −14,899.5% | −2,169.1% | −1,047.6% | −1,232.7% |
| Free cash flow margin | — | −3,706.0% | −8,722.8% | — | −1,022.5% | −992.0% |
| Rule of 40 (growth + FCF margin) | — | — | −8,747.4% | — | −943.5% | −983.7% |
| Return on capital | — | — | — | — | — | — |
| Return on equity | — | −136.2% | −144.4% | −508.0% | −2,956.4% | −710.6% |
| Return on assets | — | −91.8% | −122.8% | −176.2% | −157.0% | −163.0% |
| Net debt to EBITDA | — | — | — | — | — | — |